Upadacitinib is a once daily oral medicine belongs to a new class of oral medicines called janus kinase or JAK inhibitors. Janus kinases are enzymes that play a role in inflammation and RA. JAK inhibitors block the activity of these enzymes leading to a reduction in inflammation and are showing significant benefit to individuals with RA
In a recently reported 12-week study evaluating two doses of upadacitinib 64 percent of patients given a 15-milligram dose and 66 percent of patients given a 30-mg dose experienced a 20 percent reduction in symptoms, measured using a commonly used rheumatoid arthritis scale.
In addition there are currently two new reports in the medical journal Arthritis & Rheumatology evaluating the effectiveness and safety of another selective JAK-1 inhibitor, ABT-494, in treating RA in individuals with an inadequate response to treatment with methotrexate (MTX) or a TNF inhibitor. 1,2,3
Taken together all these reports suggest JAK inhibitors are safe, effective and should become incorporated into the overall management of RA giving physicians a new tool for the management of this condition.
Upadacitinib is also being evaluating for several other autoimmune conditions, including psoriatic arthritis, Crohn's disease and ulcerative colitis.
Tags: autoimmune conditions, crohn's disease, JAK inhibitors, janus kinase inhibitors, News Tips and Features, News Tips and Features Other, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Upadacitinib